Abstract: The ultraviolet therapy apparatus includes a light source part having an LED light source, a controller that controls lighting of the LED light source, an input unit that inputs a set irradiation dose of a therapeutic light to be applied to a patient on the assumption that a reference light is used for the therapeutic light, a storage unit that stores at least one parameter for modifying the set irradiation dose. The controller includes a modifier that modifies the set irradiation dose on the basis of the parameter stored in the storage unit, and a lighting controller that causes the LED light source to provide the modified irradiation dose. The modified irradiation dose is derived from a degree of effect of the reference light on a human body and a degree of effect on the human body caused by the ultraviolet light output from the light source part.

Abstract: An ultraviolet therapy apparatus having an LED light source can achieve a stable therapeutic effect regardless of the temperature of the LED light source. The ultraviolet therapy apparatus includes an LED light source configured to emit light including ultraviolet light; a controller configured to control lighting of the LED light source; and a measurement unit configured to detect change in a temperature of the LED light source from a reference temperature. The controller includes a calculator configured to calculate a modifying value for modifying an irradiation dose of the ultraviolet light on the basis of change in a degree of effect on a human body caused by change in spectral spectrum of the light due to change in the temperature detected by the measurement unit, and a lighting controller configured to cause the LED light source to emit the light on the basis of the modifying value calculated by the calculator.

Abstract: Provided is a technique for improving the translation efficiency of mRNA. The mRNA includes: a 5? untranslated region of an mRNA encoding a protein; and a 3? untranslated region having 40% or more and 80% or less complementarity to the 5? untranslated region.

Abstract: An object of the present invention is to prepare a functional intestinal organoid from pluripotent stem cells. An intestinal organoid is prepared from pluripotent stem cells, by the following steps (1) to (4): (1) differentiating pluripotent stem cells into endoderm-like cells; (2) differentiating the endoderm-like cells obtained in step (1) into intestinal stem cell-like cells; (3) culturing the intestinal stem cell-like cells obtained in step (2) to form spheroids; and (4) differentiating the spheroids formed in step (3) to form an intestinal organoid, the step including culture in the presence of a MEK1/2 inhibitor, a DNA methylation inhibitor, a TGF-? receptor inhibitor, and a ?-secretase inhibitor, in addition to an epidermal growth factor, a BMP inhibitor, and a Wnt signal activator.

Abstract: The present invention provides a versatile method which has a high diagnostic accuracy rate on the suitability of esophageal cancer for endoscopic therapy and enables the simple and objective determination of the suitability or unsuitability for endoscopic therapy.

Abstract: A screening system provided with a potential-dependent Na ion channel that extends the duration of the action potential associated with depolarization, and a K ion channel that deepens the resting membrane potential in the negative direction, said screening system furthermore including cells provided with ion channels that contribute to deepening the resting membrane potential in the negative direction and/or shortening the duration of the action potential as target ion channels. By such cells, the action of a test compound on the target ion channel can be easily evaluated by providing an inhibitor for the K ion channel to control the probability of cell death.

Abstract: It is an object to provide a culture method which is capable of maintaining and/or culturing iPS cell-derived intestinal stem cells, while maintaining the properties of intestinal stem cells. The induced pluripotent stem cell-derived intestinal stem cell-like cells are cultured in the presence of a GSK-3? inhibitor, a histone deacetylation inhibitor, and a serum replacement, or in the presence of a GSK-3? inhibitor and a serum replacement. Preferably, the culture is carried out under conditions in which one or more compounds selected from the group consisting of an epidermal growth factor, a TGF? receptor inhibitor and a fibroblast growth factor are further present.

Abstract: To provide a method of inducing regulatory T cells without the use of additives, disclosed herein is a method of inducing regulatory T cells comprising: a step of extracting blood from a living body; and a step of irradiating the extracted blood with ultraviolet light having a wavelength ranging between 260 nm and 320 nm. By irradiating the blood with ultraviolet light in the above specific wavelength range, it makes it possible for regulatory T cells to be induced without adding any substance to the blood extracted from a living body.

Abstract: Provided is a technique of predicting prognosis of skin cancer. A method for prognosis prediction of skin cancer includes: a step of obtaining a correlation amount correlated with an expression level of a glucose-6-phosphate dehydrogenase in a sample collected from a patient with the skin cancer; and a step of determining that the prognosis of the skin cancer is poorer when the correlation amount is large than that when the correlation amount is small.

Abstract: Provided is a technology allowing for stable supply of brain microvascular endothelium-like cells. This coating agent for inducing differentiation of pluripotent stem cells into brain microvascular endothelium-like cells contains at least one component of a Laminin-221 fragment or an N-terminal Vitronectin.

Abstract: The present invention provides a novel method for detecting an indicator of T cell lymphoma. The method for detecting an indicator of T cell lymphoma includes the step of detecting acetylated tubulin in a T cell that has been collected from a subject.

Abstract: Provided is a novel fluorescent probe. A compound of the following general formula (I) or a salt thereof.

Abstract: An object of the present invention is to provide a novel method which enables convenient preparation of cells exhibiting functions close to that of intestinal epithelial cells of living bodies, and use of the method. The differentiation of induced pluripotent stem cells into intestinal epithelial cells is induced by step of differentiating induced pluripotent stem cells into endoderm-like cells; step of differentiating the endoderm-like cells obtained in step into intestinal stem cell-like cells; and step of differentiating the intestinal stem cell-like cells obtained in step into intestinal epithelial cell-like cells, wherein step includes culture in the presence of a MEK1 inhibitor, a DNA methyltransferase inhibitor, a TGF-? receptor inhibitor, and EGF and under the condition that cAMP is supplied to the cells.

Abstract: A highly practical biomarker that is specific to esophageal cancer and minimally invasive is provided. hsa-miR-619-5p in urine, hsa-milt-1273f in urine, hsa-miR-3135b in urine, hsa-miR-4327 in urine, and hsa-miR-150-3p in urine were identified as esophageal cancer biomarkers. Esophageal cancer contraction is determined by using the expression level of these microRNAs as an index.

Abstract: An object of the present invention is to provide a marker useful for early diagnosis and differentiation of Alzheimer's disease, and use thereof. An Alzheimer's disease biomarker composed of blood flotillin is provided.

Abstract: Provided are anti-PAD4 antibodies having excellent properties and an excellent method for treatment of RA. Used are anti-PAD4 antibodies that specifically bind to an epitope containing positions 345, 347, and 348 of PAD4. These anti-PAD4 antibodies may inhibit the citrullination activity of PAD4. In addition, these anti-PAD4 antibodies may have a KD (M) of 9.0×10?9 or less. Optionally, the anti-PAD4 antibody and a TNF? inhibitor are used in combination.

Abstract: Provided is a phototherapeutic apparatus including: a probe that is held and operated by a user and provided with a photo-irradiation unit that performs irradiation with light beams; and a body provided with a control unit that controls the light beams. The body is provided with a read unit that reads a treatment protocol registered in an IC card (mobile memory medium), and a monitor (operation indication unit) that indicates a region to be irradiated with the light beams to the user, the region being set in the treatment protocol, and the control unit causes the monitor to indicate the region to be irradiated and causes the photo-irradiation unit to perform the irradiation with the light beams at a set value set in the treatment protocol. It is possible to perform the irradiation with the light beams in accordance with the treatment protocol and safely use the phototherapeutic apparatus.

Abstract: It is a subject to provide a means of preparing highly pure vascular endothelial progenitor cells in a simple and low-cost manner. It is also a subject to provide a method for efficiently proliferating vascular endothelial progenitor cells. High-purity vascular endothelial progenitor cells are prepared by the process of differentiating pluripotent stem cells into vascular endothelial progenitor cells and purifying the vascular endothelial progenitor cells using a difference in adhesion ability between the vascular endothelial progenitor cells constituting the cell population obtained in the process and other cells. On the other hand, vascular endothelial progenitor cells are cultured and expanded in the presence of a ROCK inhibitor, a GSK-3? inhibitor, and a TGF-? receptor inhibitor in addition to basic fibroblast growth factor and epidermal growth factor.

Abstract: An object of the present invention is to provide a pharmaceutical composition useful as a novel anti-hepatitis B virus agent and a screening method. According to the present invention, there is provided a pharmaceutical composition that inhibits a production of a hepatitis B virus protein, in which the pharmaceutical composition inhibits an expression or a function of an RNA-binding protein that binds to at least one sequence selected from a hepatitis B virus RNA sequence corresponding to an enhancer I region sequence on a hepatitis B virus genome DNA or a hepatitis B virus RNA sequence corresponding to an enhancer II region sequence on the hepatitis B virus genome DNA.

Abstract: An object is to prepare an intestinal organoid having a characteristic close to the small intestine of a living body, from a pluripotent stem cell. An intestinal organoid is prepared from a pluripotent stem cell, by the following steps of: (1) differentiating the pluripotent stem cell into an endoderm-like cell; (2) differentiating the endoderm-like cell obtained in step (1) into an intestinal stem cell-like cell; (3) culturing the intestinal stem cell-like cell obtained in step (2) in the presence of an epidermal growth factor, a fibroblast growth factor, a TGF ? receptor inhibitor, a GSK-3 ? inhibitor, and a ROCK inhibitor; (4) culturing the cell obtained in step (3) to form a spheroid; and (5) differentiating the spheroid formed in step (4) to form an intestinal organoid, wherein the differentiation includes culturing in the presence of an epidermal growth factor, a BMP inhibitor, and a Wnt signal activator.